Conyers Dill & Pearman provided Bermuda legal advice to Valeant Pharmaceuticals International, Inc. (“Valeant”) on its US$1.5 Billion bond offering of 9.0% senior notes due 2025.
Valeant is a specialty pharmaceutical company that develops, manufactures and markets a wide range of branded generics, branded and generic pharmaceuticals, over-the-counter (OTC) products and medical devices. Valeant is headquartered in both Laval, Quebec, Canada and Bridgewater, New Jersey, United States, and markets its products to over 100 countries globally.
Director Marcello Ausenda, and Associates Kathleen Moniz and Alexandra MacDonald from Conyers’ Bermuda office advised on the matter working alongside Davis Polk & Wardwell LLP in New York, United States.
